

Role of Leptin and dyslipidemia in chronic kidney disease

Sabeela Noor¹, Faiza Alam², Syeda Sadia Fatima², Mahnur Khan³ and Rehana Rehman^{2*}

¹Department of Biochemistry, Jinnah Medical & Dental College, Karachi, Pakistan

²Department of Biological and Biomedical Sciences, Aga Khan University, Karachi, Pakistan

³Medical College, Aga Khan University, Karachi, Pakistan

Abstract: Chronic kidney disease (CKD) patients are at an increased risk of cardiovascular complications and plasma leptin level is elevated in cardio renal syndrome. We wanted to explore leptin levels in patients with different stages of CKD and find its association with risk of cardiovascular disease. This cross-sectional study was conducted in Nephrology Department of Jinnah Post Graduate Medical Centre (JPMC) from January 2014 to September 2014. Group I comprised of controls (GFR=116±8.3, n = 44) acquired from general population, CKD patients were grouped as II, III and IV respectively with GFR; 85.77±9.9 (n = 42), 53.84±9.9 (n=42) and 20.22±8.4 (n = 42). CKD patients with any inflammatory disease, Diabetes Mellitus and on steroid therapy were excluded. Serum leptin, lipid profile and C reactive proteins (CRP) were measured. Leptin and CRP levels increased significantly with progression of CKD. High density lipoproteins (HDL) to low density lipoproteins (LDL) ratio was significantly high in control as compared to CKD groups (p<0.001). A positive correlation of leptin was observed with CRP and HDL/LDL ratio (r= 0.994, p<0.001 and r=-0.403 p<0.001) respectively. Hyperleptinemia observed with progression of CKD contributed to pathogenesis of cardiovascular disease by decreasing HDL/LDL ratio.

Keywords: Chronic Kidney disease, C reactive protein, Leptin, HDL/LDL ratio.

INTRODUCTION

End-stage renal disease (ESRD) is a complication of impaired renal function and chronic kidney disease (CKD) associated with increased morbidity, mortality, and increases the risk of cardiac disease (CVD). The prevalence of CKD is high in Pakistani population, since incidence of hypertension and diabetes in our inhabitants is one of the highest in the world.

CKD is linked to a series of multiple toxic physiological and metabolic functions. Diabetes and hypertension as being its complication are concomitant with lethal outcomes. An increased risk of CVD in these patients can lead to mortality (Locatelli *et al.*, 2003) which is attributed to inflammatory and oxidative stress, erythropoietin (EPO) resistance leading to anemia (Kazory and Ross 2009), vitamin D deficiency (Levin and Li 2005) and vascular calcification (Mizobuchi *et al.*, 2009). Adipocytokines such as leptin, are also potentially involved in the pathogenesis of metabolic syndrome (e.g. dyslipidemia) in End-stage renal disease (Mak and Cheung 2007).

Leptin is an adipose tissue-derived hormone that has been associated to numerous metabolic and inflammatory factors involved in the pathogenesis of hypertension and cardiovascular disease (Wannamethee *et al.*, 2007). Increased leptin levels are in response to high energy deposition in the form of adipocytes and obesity, irrespective of the degree of BMI (Fatima *et al.*, 2013). In renal disease the scenario is much different, as the initially CKD may be altered with change in grades of

obesity; and therefore increasing leptin levels and resistance (fig. 1). Hyperleptinemia is observed in patients during CKD progression and potentially anorexic-cachectic syndrome. However, histological changes in the basement membrane from initial to end stage disease may also contribute to the decreased levels of leptin at the end stage of CKD (Becker *et al.*, 2005). Leptin is known to be important in the regulation of food desire, body composition and might also be responsible for metabolic changes during CKD leading to inflammation and loss of lean body mass (Mak *et al.*, 2006).




Fig. 1: This diagram shows the illustration of the hypothetical mechanism of etiology of Chronic Kidney Disease.

*Corresponding author: e-mail: drrehana7@gmail.com

The etiology of kidney dysfunction may initially be associated with long-standing obesity and insulin resistance, like the metabolic syndrome (MetS). Leptin is predominantly washed out from the circulation by the kidneys after the metabolic degradation in the renal tubules (Cumin *et al.*, 1996). Shamsuzzaman *et al.* (2004) established an association between serum levels of leptin and C-reactive protein (CRP) in healthy young adults. Leptin plays a role in stimulating the sympathetic system of the body leading to elevated blood pressure and deranged GFR (Carlyle *et al.*, 2002) including natriuresis (Jackson and Li 1997) to maintain the electrolyte homeostasis (Hall *et al.*, 1990). The reduced clearance of plasma leptin leads to high levels of circulating leptin probably due to feedback-loop that down regulates certain genes in hyperleptinemic patients having advanced CKD (Nordfors *et al.*, 1998).

Increased adiposity (measured in reference to BMI) is associated with increased serum leptin levels as it is recognized to be proportional to obesity. The oxidative stress caused by the activation of reactive oxygen species (ROS) during the sub clinical inflammatory condition during obesity, leads to the damage of the podocytes thus leading to advanced CKD (Sharma *et al.*, 2008).

The objective of the study was to explore leptin levels in patients with different stages of ESRD and find its association with metabolic dysfunction in CKD patients. With the agreement that obesity and hyperleptinemia both cause metabolic dysfunction in CKD patients, we selected patients with normal BMI and then studied the relationship of Leptin, inflammatory marker reactive protein and metabolic dysfunction in CKD patients.

MATERIALS AND METHODS

Study participants

This cross-sectional study was conducted in the Department of Biological and Biomedical Sciences (BBS), Aga Khan University in collaboration with the Nephrology Department of J.P.M.C. during the period of January 2014 to September 2014. Two hundred patients were recruited for the study out of which 170 subjects were enrolled in present study. CKD patients between the ages 35- 45 years without any known cardiovascular disease were recruited. We excluded the patients with Diabetes Mellitus, liver disease, acute or chronic inflammatory disease and patient on steroid therapy. Total of 170 were divided into four groups as: Group I control subjects (GFR=116±8.3, n = 44), recruited from BBS, Aga Khan University. Group II, III and IV were CKD patients with GFR; 85.77±9.9 (n = 42), 53.84±9.9 (n = 42) and 20.22±8.4 (n = 42), respectively were enrolled from Nephrology department of JPMC.

Ethics statement

The research protocol was approved by the Institutional Review Board of the Basic Medical Science Institute,

Jinnah Postgraduate Medical Centre (NO.F.1-2/2013/BMSI-E.COMT/003/ JPMC). Written informed consents were attained from study subjects and all investigations were conducted in accordance with the principles expressed in the Declaration of Helsinki. Consent for the publication of the clinical details was also obtained.

Data collection

At the time of enrollment questionnaire was employed to record the baseline demographic and clinical data of the study subjects from their medical records. All study participants were requested to come with 10-12 hours overnight fasting for sample collection. The analysis of biochemical parameters including Cholesterol, Triglycerides and HDL-c were measured by spectrophotometry using commercially available Merck kits. Low density lipoprotein (LDL-c) was measured by Friedewald's formula (Friedewald *et al.*, 1972). CRP (mg/dl) were determined by Enzyme Linked Immuno-Sorbent Assay kit method. Glomerular filtration rate (GFR) was estimated by Cockcroft & Gault equation (Cockcroft and Gault 1976). Serum leptin levels were measured by commercially available ELISA kits method. Serum HDL-cholesterol was determined by kit manufactured by Merck, France. LDL-cholesterol was calculated according to Friedewald's formula (Friedewald *et al.*, 1972). Triglycerides were determined by using Glycerol-3-Phosphate Oxidase Phenol Aminophenazone (GPO-PAP) method, by Merck, France. Serum cholesterol was estimated by enzymatic colorimetric (CHOD-PAP) method, manufactured by Merck, France (Rifai and Warnick 2006).

STATISTICAL ANALYSIS

In this study SPSS (version 11; SPSS Inc., Chicago, IL, USA) was used to statistically analyze the descriptive data of continuous variables including age, height, weight, BMI and blood pressure along with serum Cholesterol, Triglycerides, HDL-C and LDL-c mean ± standard deviation (SD). Statistical comparisons were calculated using a student t-test and Mann Whitney U test for continuous/quantitative variables. Pearson's coefficient of correlation (r) was used for the determination of the correlation of GFR levels with and lipid profile. In all statistical analysis performed p-values <0.05 were considered significant.

RESULTS


Total of 170 subjects had mean BMI of 22.32±0.9 Kg/m² and mean leptin levels 8.26±4.6 ng/ml. Leptin levels increased significantly with progression of CKD. CRP was significantly increased in CKD groups as compared to group I (table 1). In lipid profile, cholesterol, triglyceride and LDL were significantly high in CKD groups (p<0.001), while HDL was significantly low

Table 1: Comparison of biophysical and biochemical Parameters among all groups

Variable	Group I (control, n= 44) Mean $\pm$ SD	Group II (CKD Stage II, n = 42) Mean $\pm$ SD	Group III (CKD Stage III, n = 42) Mean $\pm$ SD	Group IV (CKD Stage IV, n = 42) Mean $\pm$ SD	p value
Age (year)	55.73 $\pm$ 2.47	54.78 $\pm$ 2.54	55.42 $\pm$ 3.42	57.56 $\pm$ 5.49	>0.5
Weight (kg)	58.7 $\pm$ 2.47	62.9 $\pm$ 9.7	68.311 $\pm$ 9.54	64.9 $\pm$ 9.7	<0.5
Leptin (ng/ml)	2.56 $\pm$ 1.3	6.58 $\pm$ 1.94*	10.21 $\pm$ 1.9*	13.45 $\pm$ 3.05	<0.001
CRP (mg/dl)	2.80 $\pm$ 0.84	3.2 $\pm$ 0.12	3.75 $\pm$ 0.56	4.00 $\pm$ 0.76*	<0.001
Cholesterol (mg/dl)	147.4 $\pm$ 12.28	176 $\pm$ 5.84	198 $\pm$ 9.24	229.86 $\pm$ 17.65*	<0.001
Triglycerides (mg/dl)	118.5 $\pm$ 11.66	122 $\pm$ 9.56	169 $\pm$ 8.65	186.7 $\pm$ 9.19	<0.001
HDL (mg/dl)	41.14 $\pm$ 11.86	34.85 $\pm$ 6.25	36.12 $\pm$ 5.94	30.43 $\pm$ 13.5*	<0.001
LDL (mg/dl)	80.21 $\pm$ 13.98	101.5 $\pm$ 16.52	145 $\pm$ 19.23	161.1 $\pm$ 12.95	<0.001
HDL/LDL ratio	0.7054 $\pm$ 0.08	0.5779 $\pm$ 0.08	0.46 $\pm$ 0.10	0.25 $\pm$ 0.03	<0.001

*significant as compared to controls, p<0.01, °significant as compared to group II, p<0.01, #significant as compared to controls and overweight p<0.01, significant as compared to group I, II, III p<0.01.

(p<0.001), as compared to Group I (table 1). The HDL/LDL ratio was significantly reduced with progression of CKD. A positive correlation was observed between leptin and CRP as shown in fig. 2 (r=0.994, p<0.001). Correlation of Leptin with HDL/LDL ratio showed an inverse correlation r=-0.403 with p<0.001.

**Fig. 2:** Correlation of Leptin and C-Reactive protein.

DISCUSSION

There have been various studies exploring the serum leptin levels in different conditions but none points out its relation to metabolic dysfunction in CKD Pakistani population. To fill this gap we designed this study to assess the levels of leptin and CRP in CKD patients.

Generally, high plasma concentrations of cholesterol, LDL, and to some extent high total triglyceride concentrations with low concentrations of HDL, are associated with increased atherosclerotic CVD risk (Kwan *et al.*, 2007, Thomas *et al.*, 2008). Same pattern of uremic lipid profile has been evident in our CKD population with gradual shift towards altered cholesterol, triglyceride and HDL. Various elements are concomitant with the

development of dyslipidemia in chronic renal impairment (Kwan *et al.*, 2007).

Inflammation probably plays a key role in the initiation and progression of the atherosclerotic process (Ross 1999). High serum concentrations of systemic inflammatory markers such as CRP have been associated with atherosclerosis (Stenvinkel *et al.*, 2008).

It has been observed that increased BMI of CKD patients mediate link between obesity and CVD by its effects on arterial pressure (Menendez *et al.*, 2000), inflammatory vascular response (Konstantinides *et al.*, 2001, Bodary *et al.*, 2002), and platelet aggregation (Chaldakov *et al.*, 2001, Cooke and Oka 2002). Several studies advocate that adipose tissue releases leptin (Friedman and Halaas 1998) which possesses cytokine-like properties which is responsible for elevated IL-6 and C reactive proteins. The research of our study highlight the role of Leptin in patients of normal BMI. Our study is strengthened by other studies in CKD patients where CRP was found to be associated with renal disease explained by the reactive oxygen specie being activated and causing an inflammatory condition. This inflammation under such conditions might cause altered lipid profile, thus increase risk for cardiovascular involvement (Briffa *et al.*, 2013).

CONCLUSION

Hyperleptinemia in progressive CKD patients of our population demonstrated high CRP with low HDL/LDL ratio. This association explains the relationship of raised Leptin levels and CRP in progression of CKD as well as metabolic dysregulation that may lead to pathogenesis of cardiovascular disease in advanced CKD patients.

Implication of the study

Future longitudinal studies are required to explicate the possible mechanisms by which leptin causes metabolic dys regulations in cardiovascular diseases.

REFERENCES

- Becker B, Kronenberg F, Kielstein JT, Haller H, Morath C, Ritz E and Fliser D (2005). Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: The mild and moderate kidney disease study. *Clin. J. Am. Soc. Nephrol.*, **16**(4): 1091-1098.
- Bodary PF, Westrick R J, Wickenheiser K J, Shen Y and Eitzman DT (2002). Effect of leptin on arterial thrombosis following vascular injury in mice. *JAMA*, **287**(13): 1706-1709.
- Briffa J F, McAinch A J, Poronnik P and Hryciw DH (2013). Adipokines as a link between obesity and chronic kidney disease. *Am. J. Physiol. Renal. Physiol.*, **305**(12): F1629-F1636.
- Carlyle M, Jones O B, Kuo JJ and Hall JE (2002). Chronic cardiovascular and renal actions of leptin role of adrenergic activity. *Hypertension*, **39**(2): 496-501.
- Chaldakov G, Fiore M, Stankulov I, Hristova M, Antonelli A, Manni L, Ghenev P, Angelucci F and Aloe L (2001). NGF, BDNF, leptin and mast cells in human coronary atherosclerosis and metabolic syndrome. *Arch. Physiol. and Biochem.*, **109**(4): 357-360.
- Cockcroft D W and Gault MH (1976). Prediction of creatinine clearance from serum creatinine. *Nephron*, **16**(1): 31-41.
- Cooke JP and Oka R K (2002). Does leptin cause vascular disease? *Circulation*, **106**(15): 1904-1905.
- Cumin F, Baum H and Levens N (1996). Leptin is cleared from the circulation primarily by the kidney. *Inter. J. Obes. and Metabol. Dis., J. Inter. Assoc. Study of Obes.*, **20**(12): 1120-1126.
- Fatima S S, Bozaoglu K, Rehman R, Alam F and Memon AS (2013). Elevated chemerin levels in Pakistani men: An interrelation with metabolic syndrome phenotypes. *PLoS One*, **8**(2): e57113.
- Friedewald WT, Levy RI and Fredrickson DS (1972). Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. *Clinic Chem*, **18**(6): 499-502.
- Friedman JM and Halaas JL (1998). Leptin and the regulation of body weight in mammals. *Nature*, **395**(6704): 763-770.
- Hall JE, Mizelle HL, Hildebrandt DA and Brands MW (1990). Abnormal pressure natriuresis. A cause or a consequence of hypertension? *Hypertension*, **15**(6 Pt 1): 547-559.
- Jackson EK and Li P (1997). Human leptin has natriuretic activity in the rat. *Am. J. Physiol-Renal Physiol.*, **272**(3): F333-F338.
- Kazory A and Ross EA (2009). Anemia: the point of convergence or divergence for kidney disease and heart failure? *J. Am. Coll. Cardiol.*, **53**(8): 639-647.
- Konstantinides S, Schäfer K, Koschnick S and Loskutoff DJ (2001). Leptin-dependent platelet aggregation and arterial thrombosis suggests a mechanism for atherothrombotic disease in obesity. *J. Clin. Invest.*, **108**(10): 1533.
- Kwan B C, Kronenberg F, Beddhu S and Cheung A K (2007). Lipoprotein metabolism and lipid management in chronic kidney disease. *J. Am. Soc. Nephrol.*, **18**(4): 1246-1261.
- Levin A and Li Y C (2005). Vitamin D and its analogues: Do they protect against cardiovascular disease in patients with kidney disease & quest. *Kidney Internl.*, **68**(5): 1973-1981.
- Locatelli F, Pozzoni P, Tentori F and Del Vecchio L (2003). Epidemiology of cardiovascular risk in patients with chronic kidney disease. *Nephrol. Dial. Transplant.*, **18**(suppl 7): vii2-vii9.
- Mak R, Cheung W, Cone R and Marks D (2006). Leptin and inflammation-associated cachexia in chronic kidney disease. *Kidney Intern.*, **69**(5): 794-797.
- Mak RH and Cheung W (2007). Adipokines and gut hormones in end-stage renal disease. *Periton. Dial. Intern.*, **27**(Supplement 2): S298-S302.
- Menendez C, Baldelli R, Lage M, Casabiell X, Pinero V, Solar J, Dieguez C and Casanueva FF (2000). The in vitro secretion of human leptin is gender-dependent but independent of the body mass index of the donors. *Europ. J. Endocrinol.*, **143**(5): 711-714.
- Mizobuchi M, Towler D and Slatopolsky E (2009). Vascular calcification: The killer of patients with chronic kidney disease. *J. Amer. Soc. Nephrol.*, **20**(7): 1453-1464.
- Nordfors L, Lönnqvist F, Heimbürger O, Danielsson A, Schalling M and Stenvinkel P (1998). Low leptin gene expression and hyperleptinemia in chronic renal failure. *Kidney Intern.*, **54**(4): 1267-1275.
- Rifai N and Warnick GR (2006). Lipids, lipoproteins, apolipoproteins and other cardiovascular risk factors. *Tietz Textbook of Clinical Chemistry and Molecular Diagnostics*, **26**: 903-981.
- Ross R (1999). Atherosclerosis is an inflammatory disease. *Amer. heart. J.*, **138**(5): S419-S420.
- Shamsuzzaman A S, Winnicki M, Wolk R, Svatikova A, Phillips B G, Davison D E, Berger P B and Somers V K (2004). Independent association between plasma leptin and C-reactive protein in healthy humans. *Circulation*, **109**(18): 2181-2185.
- Sharma K, RamachandraRao S, Qiu G, Usui H K, Zhu Y, Dunn SR, Ouedraogo R, Hough K, McCue P and Chan L (2008). Adiponectin regulates albuminuria and podocyte function in mice. *J. Clin. Investig.*, **118**(5): 1645.
- Stenvinkel P, Carrero JJ, Axelsson J, Lindholm B, Heimbürger O and Massy Z (2008). Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: How do new pieces fit into the uremic puzzle? *Clinical Jour. of the Am. Soc. Nephrol.*, **3**(2): 505-521.

- Thomas R, Kanso A and Sedor JR (2008). Chronic kidney disease and its complications. *Primary Care: Clinics in Office Practice*, **35**(2): 329-344.
- Wannamethee SG, Tchernova J, Whincup P, Lowe GD, Kelly A, Rumley A, Wallace AM and Sattar N (2007). Plasma leptin: associations with metabolic, inflammatory and haemostatic risk factors for cardiovascular disease. *Atherosclerosis*, **191**(2): 418-426.